Royce & Associates LP decreased its holdings in shares of CorMedix Inc (NASDAQ:CRMD – Free Report) by 23.7% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,659,947 shares of the company’s stock after selling 516,415 shares during the period. Royce & Associates LP’s holdings in CorMedix were worth $12,782,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in CorMedix during the 2nd quarter worth $49,644,000. Pacer Advisors Inc. raised its position in CorMedix by 128.7% in the first quarter. Pacer Advisors Inc. now owns 580,620 shares of the company’s stock valued at $3,942,000 after purchasing an additional 326,724 shares during the period. Hennion & Walsh Asset Management Inc. raised its position in CorMedix by 150.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 438,629 shares of the company’s stock valued at $3,443,000 after purchasing an additional 263,618 shares during the period. Bank of New York Mellon Corp purchased a new position in CorMedix in the second quarter valued at about $3,108,000. Finally, Empowered Funds LLC lifted its stake in shares of CorMedix by 102.1% during the first quarter. Empowered Funds LLC now owns 266,637 shares of the company’s stock worth $1,810,000 after purchasing an additional 134,733 shares in the last quarter. 34.18% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several brokerages have recently weighed in on CRMD. Weiss Ratings downgraded CorMedix from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, November 10th. UBS Group set a $19.00 target price on CorMedix in a report on Tuesday, November 10th. Royal Bank Of Canada boosted their price target on CorMedix from $14.00 to $15.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 10th. Wall Street Zen cut CorMedix from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Oppenheimer restated an “outperform” rating and issued a $13.00 price target (down from $15.00) on shares of CorMedix in a report on Friday. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, CorMedix has a consensus rating of “Moderate Buy” and an average target price of $15.22.
Insider Activity
In other CorMedix news, CEO Joseph Todisco bought 80,000 shares of the company’s stock in a transaction dated Friday, November 13th. The shares were acquired at an average cost of $4.89 per share, with a total value of $391,200.00. Following the completion of the transaction, the chief executive officer owned 854,749 shares in the company, valued at $4,179,722.61. The trade was a 10.33% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.50% of the company’s stock.
CorMedix Stock Performance
CorMedix stock opened at $4.82 on Tuesday. CorMedix Inc has a 12-month low of $4.65 and a 12-month high of $13.02. The company has a market capitalization of $375.67 million, a price-to-earnings ratio of 3.75, a price-to-earnings-growth ratio of 0.90 and a beta of 1.48. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.56 and a quick ratio of 2.36. The firm’s fifty day moving average price is $7.11 and its 200 day moving average price is $7.55.
CorMedix (NASDAQ:CRMD – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.07). The firm had revenue of $54.52 million during the quarter, compared to analysts’ expectations of $51.76 million. CorMedix had a net margin of 15.49% and a return on equity of 27.12%. On average, research analysts forecast that CorMedix Inc will post 0.52 EPS for the current fiscal year.
CorMedix Company Profile
CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.
Further Reading
- Five stocks we like better than CorMedix
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding CRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CorMedix Inc (NASDAQ:CRMD – Free Report).
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
